novel transcript, antisense to filamin A

This target corresponds to an uncharacterized, non-coding antisense RNA that overlaps the FLNA gene in the human genome. "Antisense to FLNA" indicates the transcript is produced from the DNA strand opposite the coding (sense) strand for FLNA, a gene that encodes Filamin A, an actin-binding protein. Although antisense RNAs as a class are known to modulate gene expression by mechanisms such as chromatin remodeling, modulation of mRNA stability, and transcriptional interference, there is currently no evidence that ENSG00000285018 encodes a protein, acts as a receptor, enzyme, or transporter, or has disease relevance or known drug interactions[1][2][3]. Its biological function remains speculative and likely regulatory, if any, through effects on the chromatin landscape or modulation of FLNA expression, as shown for antisense transcripts in general. Key points: - This entry is a *new, uncharacterized non-coding RNA* and does *not* fit into canonical target classes such as receptors, enzymes, or transporters. - It is *not considered a therapeutic target* in the standard sense, nor are there known interacting drugs, mechanisms of drug action, or clinical biomarkers associated with it. - The "target" is therefore *likely not appropriate for inclusion in structured drug-target databases* unless enhanced functional genomics provides more evidence. - The entry appears to be a byproduct of transcriptome annotation and *is not a standard drug discovery target*. If your intent was to identify therapeutic protein-coding targets, ENSG00000285018 ("novel transcript, antisense to FLNA") should be flagged as incorrect for most drug discovery pipelines.

Other names

ENSG00000285018antisense RNA to FLNA

Not applicable (no drugs characterized; general mechanisms for antisense RNAs include transcriptional interference, RNA masking, dsRNA-dependent mechanisms, chromatin remodeling)[3]